Annelisa M Cornel, Loutje van der Sman, Jip T van Dinter, Marta Arrabito, Ester Dunnebach, Marliek van Hoesel, Thomas A Kluiver, Ana P Lopes, Noël M M Dautzenberg, Linde Dekker, Jorik M van Rijn, Denise A M H van den Beemt, Juliane L Buhl, Aimee du Chatinier, Farnaz Barneh, Yuyan Lu, Luca Lo Nigro, Anja Krippner-Heidenreich, Zsolt Sebestyén, Jurgen Kuball, Esther Hulleman, Jarno Drost, Sebastiaan van Heesch, Olaf T Heidenreich, Weng Chuan Peng, Stefan Nierkens
Human leukocyte antigen (HLA) restriction of conventional T-cell targeting introduces complexity in generating T-cell therapy strategies for patients with cancer with diverse HLA-backgrounds. A subpopulation of atypical, major histocompatibility complex-I related protein 1 (MR1)-restricted T-cells, distinctive from mucosal-associated invariant T-cells (MAITs), was recently identified recognizing currently unidentified MR1-presented cancer-specific metabolites. It is hypothesized that the MC.7.G5 MR1T-clone has potential as a pan-cancer, pan-population T-cell immunotherapy approach...
March 21, 2024: Journal for Immunotherapy of Cancer